A phase II study of cisplatin /S-1 in patients with carcinomas of unknown primary site

Asuka Tsuya, Takayasu Kurata, Akihiro Tamiya, Isamu Okamoto, Shinya Ueda, Daisuke Sakai, Naotoshi Sugimoto, Koji Matsumoto, Isao Goto, Nobuyuki Yamamoto, Masahiro Fukuoka, Kazuhiko Nakagawa

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)


Background Carcinomas of unknown primary site (CUPs) are heterogeneous tumors associated with a poor prognosis. This phase II trial was designed to evaluate the efficacy and safety of a novel combination chemotherapy of S-1 and cisplatin (CDDP) in patients with CUP. Patients and Methods Patients with previously untreated CUPs were eligible for this trial. The treatment schedule consisted of oral S-1 (40 mg/m2) twice a day on days 1-21, and intravenous CDDP (60 mg/m2) on day 8. This schedule was repeated every 5 weeks. Results A total of 46 patients were enrolled. The overall response rate and the disease control rate were 41.3 % and 80.4 %, respectively. The median overall survival time was 17.4 months. Grade 3/4 neutropenia, thrombocytopenia, and febrile neutropenia occurred in 28.3 %, 13.0 %, and 2.2 % of the patients, respectively. Conclusion CDDP plus S-1 combination chemotherapy is well tolerated and active first-line empiric therapies for patients with CUP.

Original languageEnglish
Pages (from-to)1568-1572
Number of pages5
JournalInvestigational New Drugs
Issue number6
Publication statusPublished - Dec 2013
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'A phase II study of cisplatin /S-1 in patients with carcinomas of unknown primary site'. Together they form a unique fingerprint.

Cite this